In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Modeling Pharmacogenomics' Impact

Executive Summary

With the intuitive appeal of pharmacogenomics (PGX) now largely accepted, pharmaceutical companies are wrestling with whether and how to incorporate PGX information into their drug discovery, development, and marketing processes. Yet largely absent from the advocacy of the pharmacogenomicists is a detailed discussion of the impact PGX could have on market share and average drug revenues. Based on discussions with industry leaders and using data from markets for certain existing drugs, the authors, members of the consultancy AT Kearney, developed a set of assumptions and constructed a framework to quantify the impact of PGX on both the revenues of the average drug and on the overall size of the pharmaceutical market for a given indication.
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV001553

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel